Ergoferon 20 pcs. lozenges

Treatment of influenza and acute respiratory viral infections (ARVI) in adults and children aged 6 months and older.
Treatment of acute intestinal infections of viral etiology (AIVI) in adults and children aged 6 months and older.
Non-specific prevention of COVID-19 during vaccination between the administration of the first and second components of the vaccine against the new coronavirus infection in adults.

The tablet is not intended to be divided into parts.
For oral use, not during meals. The tablet should be held in the mouth without swallowing until completely dissolved.
When prescribing the medication to younger children (from 6 months to 3 years), it is recommended to dissolve the tablet in a small amount (1 tablespoon) of boiled water at room temperature.
Treatment of influenza, ARVI, and OVI
Adults and children from 6 months. On the first day of treatment, take 8 tablets according to the following scheme: 1 tablet every 30 minutes for the first 2 hours (a total of 5 tablets in 2 hours), then on the same day take 1 tablet 3 more times at equal intervals. On the 2nd day and thereafter, take 1 tablet 3 times a day until full recovery.
If necessary, the medication can be combined with other antiviral and symptomatic agents.
Non-specific prevention of COVID-19 during vaccination between the administration of the first and second components of the vaccine against the new coronavirus infection in adults
Adults. 1 tablet per dose 2 times a day. Duration of intake up to 3 weeks.

Composition (per 1 tablet)
Active ingredients:
affinity-purified antibodies to human gamma interferon - 10,000 EMU*,
affinity-purified antibodies to histamine - 10,000 EMU*,
affinity-purified antibodies to CD4 - 10,000 EMU*.
Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.

• EMU - units of modifying action.

Tablets in a flat-cylindrical shape, with a score line and beveled edges, from white to almost white in color. The flat side with the score line is imprinted with the inscription MATERIA MEDICA, while the other flat side bears the inscription ERGOFERON.

Increased individual sensitivity to the components of the drug.
Lactase deficiency, hereditary galactose intolerance, glucose-galactose malabsorption.
Children under 6 months of age - for the treatment of influenza, ARVI, and OKVI.
Children under 18 years of age - for nonspecific prevention of COVID-19 during vaccination between the administration of the first and second components of the vaccine against the new coronavirus infection.

Use during pregnancy and breastfeeding
The safety of using Ergoferon® in pregnant women has not been studied.
During pregnancy and lactation, the drug is used only if the expected benefit to the mother outweighs the potential risk to the fetus and child. The "benefit-risk" ratio is determined by the attending physician.

The preparation contains lactose monohydrate, therefore it is not recommended for patients with congenital galactosemia, glucose malabsorption syndrome, or congenital lactase deficiency.

Effect on the ability to drive vehicles and operate machinery
Ergoferon® does not affect the ability to drive vehicles and operate other potentially dangerous machinery.

Possible reactions of increased individual sensitivity to the components of the medication. If you experience any adverse reactions listed in the instructions, or if they worsen, or if you notice any other adverse reactions not mentioned in the instructions, inform your doctor.

In case of overdose, dyspeptic symptoms may occur due to the excipients contained in the preparation. Treatment involves discontinuation of the medication and administration of symptomatic therapy, such as oral rehydration.

No cases of incompatibility with other medications have been reported to date.

The pharmacological activity spectrum of the drug Ergoferon® includes antiviral, immunomodulatory, antihistaminic, and anti-inflammatory effects.
The components of the drug have a unified mechanism of action in the form of increased functional activity of CD4 receptors, gamma interferon (IFNγ) receptors, and histamine receptors, respectively, which is accompanied by a pronounced immunotropic effect.
Experimental evidence shows that antibodies to gamma interferon: increase the expression of IFNγ, IFNa/β, as well as associated interleukins (IL-2, IL-4, IL-10, etc.); improve ligand-receptor interaction of IFN; restore cytokine status; normalize the concentration and functional activity of natural antibodies to IFNγ, which are an important factor in the body's natural antiviral tolerance; stimulate interferon-dependent biological processes: induction of expression of major histocompatibility complex I and II type antigens and Fc receptors, activation of monocytes, stimulation of NK cell functional activity, regulation of immunoglobulin synthesis, activating a mixed Th1 and Th2 immune response.
Antibodies to CD4, likely acting as allosteric modulators of this receptor, regulate the functional activity of the CD4 receptor, leading to increased functional activity of CD4+ lymphocytes, normalization of the immunoregulatory index CD4+/CD8+, as well as the subpopulation composition of immune competent cells (CD3+, CD4+, CD8+, CD16+, CD20+).
Antibodies to histamine modify histamine-dependent activation of peripheral and central H1 receptors and thus reduce the tone of smooth muscle in the bronchi, decrease capillary permeability, which leads to a reduction in the duration and severity of rhinorrhea, nasal mucosa edema, cough, and sneezing, as well as a decrease in the severity of allergic reactions associated with the infectious process by suppressing the release of histamine from mast cells and basophils, production of leukotrienes, synthesis of adhesion molecules, reduction of eosinophil chemotaxis, and platelet aggregation in reactions to contact with allergens.
The combined use of the components of the complex drug is accompanied by an enhancement of the antiviral activity of its components.
In the course of experimental and clinical studies, therapeutic efficacy was established against influenza viruses, parainfluenza, rhinovirus, metapneumovirus, seasonal strains of coronaviruses, bocavirus, respiratory syncytial virus, respiratory and intestinal strains of adenoviruses, rotaviruses, noroviruses, astroviruses, as well as non-specific preventive efficacy against SARS-CoV-2. In a clinical study, a threefold reduction in the risk of COVID-19 was established during the vaccination period between the administration of the I and II components of the "Gam-COVID-Vac" vaccine against the background of preventive use of the drug Ergoferon®.

The sensitivity of modern physicochemical analysis methods (gas-liquid chromatography, high-performance liquid chromatography, chromatographic mass spectrometry) does not allow for the assessment of the content of active substances of the Ergoferon® preparation in biological fluids, organs, and tissues, which makes it technically impossible to study pharmacokinetics.

Ergoferon is a medication designed to stimulate the immune system and combat viral infections in the body. The product is available in the form of lozenges. Ergoferon contains 3 active components: antibodies to gamma interferon, antibodies to histamine, and calcium citrate.

The medication is used for the treatment and prevention of influenza, acute respiratory viral infections (ARVI), herpes, viral encephalitis, adenoviral infection, and other viral diseases. It has immunostimulating, anti-inflammatory, and antihistamine effects.

The tablets are dissolved under the tongue, making them convenient to take. The medication has no age restrictions and virtually no side effects. Ergoferon helps fight viral diseases and boosts the body's immunity.